Evolution of Cardiovascular Function and Quality of Life in Patients Included in the SCArabée Therapeutic Education Program

Sponsor
Groupe Hospitalier Mutualiste de Grenoble (Other)
Overall Status
Completed
CT.gov ID
NCT03669211
Collaborator
Fondation de l'Avenir (Other)
30
1
1
23.3
1.3

Study Details

Study Description

Brief Summary

Coronary artery disease is defined as a disease of the arteries that vascularize the heart, resulting in myocardial ischemia, i.e. insufficient blood supply to the heart muscle. Eventually, it may be responsible for acute coronary syndrome that includes unstable angina (chest pain) and myocardial infarction (necrosis of the heart muscle).

The main cause of this disease is atheroma, and management involves reducing modifiable cardiovascular risk factors (sedentary lifestyle, smoking, obesity, high blood pressure, diabetes, dyslipidemia). Every year, this disease affects more than 120 000 people in France, aging 65 years on average.

In this real public health problem, there is a significant discrepancy between the excellence of the management of the acute incident and the inadequacy of the re-adaptive and educational management of the care suites. In fact, it is noted that hospitalization times are short given the progress of myocardial revascularization, associated with a low intra-hospital mortality rate, 3% but the places in rehabilitation programs ("Soins de Suite et de Réadaptation" or "SSR") are too limited (25% of the patients are included in these programs). Physical rehabilitation has proven effective for decades, with robust evidence of decreased recurrence and mortality (-20%).

At the Groupe Hospitalier Mutualiste of Grenoble, France, patients are offered two courses of treatment in post-myocardial infarction:

  • A therapeutic education program: SCarabée,

  • A rehabilitation program (SSR) The therapeutic education program aims to help the patient identify his needs, acquire knowledge, strengthen his resources and finally develop with him a project to improve his quality of life.

SSR offers physical rehabilitation as a treatment for infarction, which improves cardiovascular function, which is assessed by the cardiorespiratory test.

Is the Scarabée therapeutic education program is sufficient to help the patient improve his physical abilities? This study aims to answer this question, by setting up a reinforced monitoring of the evolution of the cardiovascular function of the patients included in the SCArabée program, via cardiorespiratory tests. The results of this first pilot study will potentially lead to a second randomized study comparing therapeutic education associated with Adapted Physical Education versus therapeutic education alone for the improvement of cardiorespiratory functions and the quality of life of these patients.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Cardiac stress test
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Pilot, Prospective Study Assessing the Evolution of Cardiovascular Function and Quality of Life in Patients With Acute Coronary Syndrome, Included in the SCArabée Therapeutic Education Program
Actual Study Start Date :
Jan 7, 2019
Actual Primary Completion Date :
Dec 15, 2020
Actual Study Completion Date :
Dec 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cardiac stress test

Diagnostic Test: Cardiac stress test
In order to assess the evolution of their cardiorespiratory function, patients will benefit from two cardiac stress test combined with VO2 study, one at inclusion in the study, and the other one 6 months later.
Other Names:
  • Cardiac diagnostic test
  • Cardiopulmonary exercise test
  • CPX test
  • Outcome Measures

    Primary Outcome Measures

    1. Assess the evolution of cardiovascular function of patients included in the SCArabée program [At inclusion, and 6 month after inclusion]

      Endpoint : Percentage change in the VO² threshold between the two cardiac stress tests

    Secondary Outcome Measures

    1. Assess the evolution of the patient's physical activity [At inclusion, and 6 month after inclusion]

      Endpoint : Score of the "Ricci and Gagnon" questionnaire filled by the patient

    2. Assess the evolution of cardiac function [At inclusion, and 6 month after inclusion]

      Endpoint : Left Ventricular Ejection Fraction measured during the two cardiac stress tests

    3. Assess the evolution of perceived level of anxiety [At inclusion, and 6 month after inclusion]

      Endpoint : Score of the Hospital Anxiety and Depression Scale filled by the patient

    4. Assess the evolution of global quality of life [At inclusion, and 6 month after inclusion]

      Endpoint : Score of the 12-Item Short Form Health Survey (SF-12) filled by the patient

    5. Assess the evolution of weight [At inclusion, and 6 month after inclusion]

      Measured during a bioelectrical impedance analysis

    6. Assess the evolution of fat mass [At inclusion, and 6 month after inclusion]

      Measured during a bioelectrical impedance analysis

    7. Assess the evolution of visceral fat mass [At inclusion, and 6 month after inclusion]

      Measured during a bioelectrical impedance analysis

    8. Assess the evolution of muscular mass [At inclusion, and 6 month after inclusion]

      Measured during a bioelectrical impedance analysis

    9. Assess the evolution of Body Mass Index [At inclusion, and 6 month after inclusion]

    10. Assess the evolution of tobacco consumption [At inclusion, and 6 month after inclusion]

      Comparison of the number of cigarettes consumed per day between the month preceeding the Acute Coronary Syndrome event and the 6th month of follow-up

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male or female, aged 18 or older

    • Patient with newly diagnosed or recurring Acute Coronary Syndrome, or presenting a coronary heart disease detected on ischemia test and stented

    • Patient included in the SCArabée therapeutic education program

    • Patient assessed stable on the basis of a clinical examination, or exercise test, or ultrasound data

    • Patient in physical capacity to perform a cardiorespiratory test

    • Patient giving free, informed and written consent

    • Patient affiliated to the social security system

    Exclusion Criteria:
    • Impossibility to submit to follow-up of the study for geographical social or psychological reasons

    • Persons referred to in Articles L1121-5 to L1121-8 of the Public Health Code (corresponds to all persons protected): pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person making the subject of a legal protection measure

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Groupe Hospitalier Mutualiste de Grenoble Grenoble France 38028

    Sponsors and Collaborators

    • Groupe Hospitalier Mutualiste de Grenoble
    • Fondation de l'Avenir

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Groupe Hospitalier Mutualiste de Grenoble
    ClinicalTrials.gov Identifier:
    NCT03669211
    Other Study ID Numbers:
    • 2018/06-JPE-GHMG
    First Posted:
    Sep 13, 2018
    Last Update Posted:
    Jul 28, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Groupe Hospitalier Mutualiste de Grenoble
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 28, 2021